@article{oai:nagasaki-u.repo.nii.ac.jp:00006896,
 author = {Harada, Yosuke and Yanagihara, Katsunori and Yamada, Koichi and Migiyama, Yohei and Nagaoka, Kentaro and Morinaga, Yoshitomo and Nakamura, Shigeki and Imamura, Yoshifumi and Hasegawa, Hiroo and Miyazaki, Taiga and Izumikawa, Koichi and Kakeya, Hiroshi and Kohno, Shigeru},
 issue = {6},
 journal = {Antimicrobial Agents and Chemotherapy},
 month = {Jun},
 note = {Daptomycin is inactivated by pulmonary surfactant, but its effectiveness in hematogenous pulmonary infection has been poorly studied. The potential therapeutic application was evaluated in a methicillin-resistant Staphylococcus aureus (MRSA) hematogenous pulmonary infection mouse model. Compared with control results, daptomycin improved survival (P<0.001) and decreased the number of abscesses and bacteria in the lungs (P<0.01). Daptomycin may be an effective therapeutic option for MRSA hematogenous pulmonary infection., Antimicrobial Agents and Chemotherapy, 57(6), pp.2841-2844; 2013},
 pages = {2841--2844},
 title = {In Vivo Efficacy of Daptomycin against Methicillin-Resistant Staphylococcus aureus in a Mouse Model of Hematogenous Pulmonary Infection},
 volume = {57},
 year = {2013}
}